Vical, Inc. (NASDAQ:VICL)

CAPS Rating: 3 out of 5

The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

Recs

0
Player Avatar colbob2 (< 20) Submitted: 12/3/2009 5:22:50 PM : Outperform Start Price: $2.90 VICL Score: -19.84

AS A PHARMACIST I FEEL THE FUTURE IN DRUGS IS IN THE VACINE FIELD, WHICH VICL EXCELS. WITH MONEY FROM MERCK, AND SNY. I FEEL THAT THIS STOCK WILL MOVE UP NEXT YEAR AND FEEL THAT THE SELL OFF THAT IS NOW GOING ON IS A TAX RELIEF SELL OFF.

Featured Broker Partners


Advertisement